Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 3/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
| ▸ | RHEB | Q15382 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31432146 | 1.00 | AHR (0.47) | AHRCYP2A6NR4A2IMPDH2PARP1 | |
| Hydrochloric Acid SCHEMBL31432329 | 0.98 | AHR (0.45) | AHRCYP2A6NR4A2IMPDH2PARP1 | |
| SCHEMBL30949509 | 0.74 | AHR (0.52) | AHRCYP2A6NR4A2IMPDH2PARP1 | |
| SCHEMBL31431597 | 0.74 | AHR (0.38) | AHRPARP1RECQLTDP1MAPK1 | |
| SCHEMBL28906650 | 0.74 | RHEB (0.40) | AHRNR4A2IMPDH2PARP1RECQL | |
| SCHEMBL2985458 | 0.74 | AHR (0.38) | AHRPARP1RECQLTDP1MAPK1 | |
| SCHEMBL724626 | 0.74 | AHR (0.38) | AHRPARP1RECQLTDP1MAPK1 | |
| SCHEMBL13065414 | 0.74 | AHR (0.47) | AHRCYP2A6NR4A2PARP1GPR84 | |
| SCHEMBL4388854 | 0.74 | AHR (0.47) | AHRCYP2A6NR4A2PARP1MAPK1 | |
| SCHEMBL63525 | 0.74 | AHR (0.47) | AHRCYP2A6NR4A2PARP1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349988-B | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | 卡鲁斯治疗有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-10442815-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2019-10-15 | — | — | US | disclosed |
| US-10442815-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2019-10-15 | — | — | US | disclosed |
| US-20180244685-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2018-08-30 | — | — | US | disclosed |
| CN-108349988-A | tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitor | 卡鲁斯治疗有限公司 | 2018-07-31 | — | — | CN | disclosed |
| EP-3337807-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | Karus Therapeutics Ltd (GB) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017029521-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | KARUS THERAPEUTICS LTD (GB) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017029521-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | KARUS THERAPEUTICS LTD (GB) | 2017-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244685-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3CD, PIK3CA, PIK3C2B | AHR 4503/4885CYP2A6 3691/4885NR4A2 4701/4885 |
| US-10442815-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | PIK3CD, PIK3CA, PIK3C2B | AHR 4503/4885CYP2A6 3691/4885NR4A2 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.